Home・Elenco Azioni・Galectin Therapeutics Inc

Galectin Therapeutics Inc

Chiusa

SettoreSettore sanitario

2.97 -1

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2.94

Massimo

3.16

Metriche Chiave
By Trading Economics
Entrata	454K -5M
EPS	-0.08
Dipendenti	9
EBITDA	474K -3M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+270.37% upside

Dividendi
By Acuity
Utili prossimi	12 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	77M 223M
Apertura precedente	3.97
Chiusura precedente	2.97

Notizie sul Sentiment di mercato

By Acuity

25%

75%

73 / 340 Classifica in Healthcare

Galectin Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 ago 2026, 19:46 UTC

Galectin Therapeutics Inc is higher today, continuing an upward trend since Friday's close, despite pulling back from a session high. No specific news was identified.

31 lug 2026, 21:51 UTC

Galectin Therapeutics Inc is lower in after-market trading, influenced by broader market trends. The asset has faced three consecutive sessions of declines.

30 lug 2026, 20:10 UTC

Galectin Therapeutics Inc is lower today, breaking a trend of higher daily closes. Increased market volume accompanies the decline amid broader market volatility.

29 lug 2026, 18:58 UTC

Galectin Therapeutics Inc shares are higher today, continuing an upward trend since Tuesday's close. The stock remains below its 20-day moving average.

28 lug 2026, 17:46 UTC

Galectin Therapeutics Inc shares are lower today, continuing a decline since Monday's close, amid broader market caution following significant drops in Asian indices.

27 lug 2026, 16:32 UTC

Galectin Therapeutics Inc shares are lower today, reflecting a notable decline since Friday. The stock has seen unusually high trading volume amid broader market sentiment.

24 lug 2026, 20:02 UTC

Galectin Therapeutics Inc is lower today, marking its ninth consecutive session of declines. The stock remains below its 20-day moving average.

22 lug 2026, 19:01 UTC

Galectin Therapeutics Inc. shares are trading lower, following a peak earlier in the session. High trading volume indicates increased investor activity.

21 lug 2026, 17:16 UTC

Galectin Therapeutics Inc. shares are lower today, continuing a five-session decline and trading significantly below the 20-day moving average. No specific news was identified.

20 lug 2026, 20:06 UTC

Galectin Therapeutics Inc shares are lower today, continuing a trend of five consecutive daily declines amid broader market volatility linked to geopolitical tensions.

Confronto tra pari

Modifica del prezzo

Galectin Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

270.37% in crescita

Previsioni per 12 mesi

Media 11 USD 270.37%

Alto 11 USD

Basso 11 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Galectin Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 1 che hanno fornito valutazioni azionarie a Galectin Therapeutics Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

73 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.